This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.
raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
Other Name: MK0518
Other Name: ISENTRESS™
Inclusion Criteria: - HIV positive patients who have limited or no treatment options and have documented resistance
Exclusion Criteria: - Patient has previously been on MK0518 therapy
Merck Sharp & Dohme Corp.